Cortisol Awakening Response Is Linked to Disease Course and Progression in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis has frequently been reported in multiple sclerosis (MS). So far, HPA axis function in MS has predominantly been studied under pharmacological stimulation which is associated with a series of methodological caveats. Knowledge of circadian cortisol patterns and cortisol awakening response (CAR) is still limited. METHODS: A total of 77 MS patients (55 relapsing-remitting MS (RRMS)/22 secondary-progressive MS (SPMS)) as well as 34 healthy control (HC) subjects were enrolled. Diurnal cortisol release was assessed by repeated salivary cortisol sampling. Neurological disability was rated by the Kurtzke's Expanded Disability Status Scale (EDSS). Depressive symptoms and perceived stress were assessed by self-report measures. RESULTS: RRMS but not SPMS patients differed in circadian cortisol release from HC subjects. Differences in cortisol release were restricted to CAR. Treated and treatment naïve RRMS patients did not differ in CAR. In a RRMS follow-up cohort (nine months follow-up), RRMS patients with EDSS progression (≥0.5) expressed a significantly greater CAR compared to HC subjects. RRMS patients with a stable EDSS did not differ from HC subjects. Neither depressive symptoms nor perceived stress ratings were associated with CAR in RRMS patients. In a step-wise regression analysis, EDSS at baseline and CAR were predictive of EDSS at follow-up (R(2) = 67%) for RRMS patients. CONCLUSIONS: Circadian cortisol release, in particular CAR, shows a course specific pattern with most pronounced release in RRMS. There is also some evidence for greater CAR in RRMS patients with EDSS progression. As a consequence, CAR might be of predictive value in terms of neurological disability in RRMS patients. The possible role of neuroendocrine-immune interactions in MS pathogenesis is further discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which is impaired in individuals with UMNDs such as MS, BI, stroke, and SCI.46–50”
From Feasibility, Acceptability, and Efficacy of Mindfulness Training in People With Upper Motor Neuron Disorders: A Systematic Review (2022) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267 · cited 3×
“Neurological disability was rated by the Kurtzke’s Expanded Disability Status Scale (EDSS).”
MethodRating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011 · cited 1×
“For MS patients, neurological impairment was rated using Kurtzke’s Expanded Disability Status Scale (EDSS) [21] based on the Neurostatus scoring system (www.”
MethodDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017 · cited 1×
“Eighty-six patients with definite MS according to revised McDonald criteria [20] as well as thirty-seven HC subjects were enrolled.”
MethodCompston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Pruessner, J. C., Kirschbaum, C., Meinlschmid, G., & Hellhammer, D. H. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00108-7 · Cited by 3,638 · cited 1×
“For CAR (samples 1–4), an area under the curve with respect to ground (AUCawakening) was calculated as previously described [25].”
MethodThe cortisol awakening response (CAR): Facts and future directions
Fries, E., Dettenborn, L., & Kirschbaum, C. (2009) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2008.03.014 · Cited by 1,188 · cited 1×
“The cortisol awakening response (CAR) is a well described phenomenon which is characterized by a pronounced increase of cortisol within 20 to 30 minutes after awakening [1,2].”
BackgroundCortisol awakening response and psychosocial factors: a systematic review and meta-analysis
Chida, Y., & Steptoe, A. (2009) · Biological Psychology · doi:10.1016/j.biopsycho.2008.10.004 · Cited by 1,032 · cited 1×
“The cortisol awakening response (CAR) is a well described phenomenon which is characterized by a pronounced increase of cortisol within 20 to 30 minutes after awakening [1,2].”
BackgroundMajor depressive disorder and hypothalamic-pituitary-adrenal axis activity
Vreeburg, S. A., Hoogendijk, W. J. G., van Pelt, J., DeRijk, R. H., Verhagen, J. C. M., van Dyck, R., Smit, J. H., Zitman, F. G., & Penninx, B. W. J. H. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.50 · Cited by 792 · cited 1×
“It is further modulated by various factors such as genetic polymorphisms [5], stressful experience [5,6,7], affective symptoms [6,8] and inflammatory states [9].”
BackgroundGenetic factors, perceived chronic stress, and the free cortisol response to awakening
Wüst, S., Federenko, I., Hellhammer, D. H., & Kirschbaum, C. (2000) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(00)00021-4 · Cited by 642 · cited 1×
“It is further modulated by various factors such as genetic polymorphisms [5], stressful experience [5,6,7], affective symptoms [6,8] and inflammatory states [9].”
BackgroundGlucocorticoids and the Th1/Th2 Balance
ELENKOV, I. J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1321.010 · Cited by 612
Pruessner, M., Hellhammer, D. H., Pruessner, J. C., & Lupien, S. J. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000040950.22044.10 · Cited by 435 · cited 2×
“It is further modulated by various factors such as genetic polymorphisms [5], stressful experience [5,6,7], affective symptoms [6,8] and inflammatory states [9].”
BackgroundSchulz, P., & Schlotz, W. (1999) · Diagnostica · doi:10.1026//0012-1924.45.1.8 · Cited by 323
Allgemeine Depressions-Skala (ADS)
Meyer, T. D., & Hautzinger, M. (2001) · Diagnostica · doi:10.1026//0012-1924.47.4.208 · Cited by 279
Effects of glucocorticoids on gene transcription
Hayashi, R., Wada, H., Ito, K., & Adcock, I. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.011 · Cited by 277 · cited 1×
“Within such a circuit, glucocorticoids (GC) have shown to inhibit the production of proinflammatory cytokines by inhibiting the nuclear transcription factor kappa B [31].”
BackgroundNakano, T., Ohara, O., Teraoka, H., & Arita, H. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38408-x · Cited by 207 · cited 1×
“GC have also shown to influence a series of immunological functions that are associated with MS pathology such as Th1/Th2 balance [32], phospholipase A2 function [33] as well as the production reactive oxygen species [34].”
BackgroundCircadian regulation of cortisol after hippocampal damage in humans
Buchanan, T. W., Kern, S., Allen, J. S., Tranel, D., & Kirschbaum, C. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.014 · Cited by 206 · cited 2×
“Interestingly, patterns reported by Yssraelit and colleagues significantly differ from course specific patterns that are based on the Dex/CRH test [12] - an effect that could possibly be explained by methodological differences in HPA axis testing: while circadian regulation reflects an inherent release pattern that is…”
BackgroundSelf-citationFassbender, K., Schmidt, R., Mößner, R., Kischka, U., Kühnen, J., Schwartz, A., & Hennerici, M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.1.66 · Cited by 204 · cited 2×
“HPA axis function also seems to be linked to radiological as well as clinical aspects: increased cortisol response to CRH was associated with gadolinium enhancing lesions, a marker for acute central nervous system inflammation in MS [14].”
BackgroundPruessner, M., Pruessner, J. C., Hellhammer, D. H., Bruce Pike, G., & Lupien, S. J. (2007) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2006.12.007 · Cited by 150 · cited 2×
“Interestingly, patterns reported by Yssraelit and colleagues significantly differ from course specific patterns that are based on the Dex/CRH test [12] - an effect that could possibly be explained by methodological differences in HPA axis testing: while circadian regulation reflects an inherent release pattern that is…”
BackgroundThe cytokine-HPA axis feed-back circuit
Besedovsky, H. O., & del Rey, A. (2000) · Zeitschrift für Rheumatologie · doi:10.1007/s003930070014 · Cited by 146 · cited 2×
“It is a well- established finding, that a series of proinflammatory cytokines can activate the HPA axis [30].”
BackgroundDeSantis, A. S., DiezRoux, A. V., Hajat, A., Aiello, A. E., Golden, S. H., Jenny, N. S., Seeman, T. E., & Shea, S. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.11.009 · Cited by 123 · cited 1×
“It is further modulated by various factors such as genetic polymorphisms [5], stressful experience [5,6,7], affective symptoms [6,8] and inflammatory states [9].”
BackgroundDysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS
Bergh, F. T., Kümpfel, T., Trenkwalder, C., Rupprecht, R., & Holsboer, F. (1999) · Neurology · doi:10.1212/wnl.53.4.772 · Cited by 112 · cited 3×
“In response to intravenous administration of CRH, cortisol release was increased in MS patients compared to healthy control subjects [12,13].”
BackgroundHuo, Y., Rangarajan, P., Ling, E.-A., & Dheen, S. T. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-49 · Cited by 112 · cited 1×
“GC have also shown to influence a series of immunological functions that are associated with MS pathology such as Th1/Th2 balance [32], phospholipase A2 function [33] as well as the production reactive oxygen species [34].”
BackgroundImpaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis
Ysrraelit, M. C., Gaitán, M. I., Lopez, A. S., & Correale, J. (2008) · Neurology · doi:10.1212/01.wnl.0000336918.32695.6b · Cited by 108
The impact of time of waking and concurrent subjective stress on the cortisol response to awakening
Williams, E. D., Magid, K. S., & Steptoe, A. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.06.006 · Cited by 103 · cited 1×
“It is further modulated by various factors such as genetic polymorphisms [5], stressful experience [5,6,7], affective symptoms [6,8] and inflammatory states [9].”
BackgroundGold, S. M., Kruger, S., Ziegler, K. J., Krieger, T., Schulz, K.-H., Otte, C., & Heesen, C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.230029 · Cited by 98 · cited 5×
“Finally, we expected diurnal cortisol patterns to be associated with treatment [19], disease progression [15], affective symptoms [16,17] and perceived stressful experience [6].”
BackgroundResultInfluentialAdrenal Size Is Increased in Multiple Sclerosis
Reder, A. T., Makowiec, R. L., & Lowy, M. T. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540140057015 · Cited by 89 · cited 1×
“A hyperactive HPA axis has often been reported in multiple sclerosis (MS): in post mortem studies enlarged adrenals [10] as well as increased activity of corticotropin-releasing-hormone (CRH) producing cells within the hypothalamus have been found [11].”
BackgroundIncreased activity of hypothalamic corticotropin-releasing hormone neurons in multiple sclerosis
Erkut, Z. A., Hofman, M. A., Ravid, R., & Swaab, D. F. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00098-m · Cited by 84 · cited 1×
“A hyperactive HPA axis has often been reported in multiple sclerosis (MS): in post mortem studies enlarged adrenals [10] as well as increased activity of corticotropin-releasing-hormone (CRH) producing cells within the hypothalamus have been found [11].”
BackgroundGrasser, A., Möller, A., Backmund, H., Yassouridis, A., & Holsboer, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211419 · Cited by 70 · cited 2×
“In response to intravenous administration of CRH, cortisol release was increased in MS patients compared to healthy control subjects [12,13].”
BackgroundHypothalamo–pituitary–adrenal axis activity predicts disease progression in multiple sclerosis
Gold, S. M., Raji, A., Huitinga, I., Wiedemann, K., Schulz, K., & Heesen, C. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.014 · Cited by 70 · cited 2×
“In a three year follow-up study, increased adrenocorticotropic hormone (ACTH) response to CRH administration has been linked to disease progression and cognitive dysfunction [15].”
BackgroundCircadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis
Kern, S., Schultheiß, T., Schneider, H., Schrempf, W., Reichmann, H., & Ziemssen, T. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.04.004 · Cited by 51 · cited 5×
“Finally, we expected diurnal cortisol patterns to be associated with treatment [19], disease progression [15], affective symptoms [16,17] and perceived stressful experience [6].”
BackgroundResultSelf-citationGoebel, M. U., Baase, J., Pithan, V., Exton, M. S., Saller, B., Schedlowski, M., & Limmroth, V. (2002) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00099-3 · Cited by 49 · cited 1×
“Treatment Effects and Circadian HPA Axis Function Acute administration of Interferon-b (INF- b) has shown to cause significant changes in cortisol release within MS patients [19] and HC subjects [27].”
BackgroundWichers, M. C., Myin-Germeys, I., Jacobs, N., Kenis, G., Derom, C., Vlietinck, R., Delespaul, P., Mengelers, R., Peeters, F., Nicolson, N., et al. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31816b1eee · Cited by 30 · cited 1×
“An increased CAR [16] as well as increased evening cortisol levels [17] have been described in MS patients with depressive symptoms and in non-MS cohorts [28,29].”
BackgroundBergh, F. T., Grasser, A., Trenkwalder, C., Backmund, H., Holsboer, F., & Rupprecht, R. (1999) · Journal of Neurology · doi:10.1007/s004150050349 · Cited by 26 · cited 1×
“[13,14,26] and endocrine changes seem to be associated with clinical course as well as disease progression.”
BackgroundSalivary cortisol in unaffected twins discordant for affective disorder
Vinberg, M., Bennike, B., Kyvik, K. O., Andersen, P. K., & Kessing, L. V. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.08.001 · Cited by 26
Acute and chronic neuroendocrine effects of interferon‐β 1a in multiple sclerosis
Bergh, F. T., Kümpfel, T., Yassouridis, A., Lechner, C., Holsboer, F., & Trenkwalder, C. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02725.x · Cited by 18 · cited 2×
“Finally, we expected diurnal cortisol patterns to be associated with treatment [19], disease progression [15], affective symptoms [16,17] and perceived stressful experience [6].”
Background
Research works printed but not linked: 1
- Schulz P, Schlotz W (1999) The Trier Inventory for Chronic Stress (TICS): scale construction, statistical testing and validation of the scale work overload. Diagnostica 45: 8– 19.
Cited by
Wahl, M., Buchholz, B., Winde, V., Golomb, D., Guy‐Haim, T., Müller, J. D., Rilov, G., Scotti, M., & Böttcher, M. E. (2015) · Limnology and Oceanography Methods · doi:10.1002/lom3.10055 · Cited by 101
Steptoe, A., & Serwinski, B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800951-2.00034-0 · Cited by 91
Morris, G., Reiche, E. M. V., Murru, A., Carvalho, A. F., Maes, M. H. J., Berk, M., & Puri, B. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0843-5 · Cited by 79
Thomas, N., Gurvich, C., Huang, K., Gooley, P. R., & Armstrong, C. W. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.100995 · Cited by 80
Biernacki, T., Kokas, Z., Sandi, D., Füvesi, J., Fricska‐Nagy, Z., Faragó, P., Kincses, Z. T., Klivènyi, P., Bencsik, K., & Vécsei, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063383 · Cited by 52
Metadata
- Authors
- Kern, S., Krause, I., Horntrich, A., Thomas, K., Aderhold, J., & Ziemssen, T.
- Affiliations
- University Hospital Carl Gustav Carus (DE)
- Corresponding author
- Kern, Simone
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-16
- Volume
- 8
- Issue
- 4
- Pages
- e60647
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3628870
- OpenAlex
- W1996708457
- Semantic Scholar
- 650daa21a1a6da8a0ff90c8548374496fc8e56fc
- Cited by
- 50
- References
- 35
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 8 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 2 · 2015: 6 · 2014: 3
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Qucosa (Saxon State and University Library Dresden) (submittedVersion, cc-by)
- Funders
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Deutsche Forschungsgemeinschaft
- Technische Universität Dresden
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- cortisol awakening response, multiple sclerosis, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, HPA axis dysregulation, disability progression, Expanded Disability Status Scale, depressive symptoms, perceived stress, neuroendocrine-immune interaction
- MeSH terms
- Adult, Female, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Middle Aged, Multiple Sclerosis, Pituitary-Adrenal System, Saliva, Case-Control Studies, Young Adult, Circadian Clocks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.